title: [Current national and international status of supportive therapy for the coagulopathy associated with L-asparaginase containing regimen for acute lymphoblastic leukemia].
abstract: We investigated supportive therapy against coagulopathy associated with L-asparaginase treatment in patients with acute lymphoblastic leukemia who were enrolled in the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG), Japan Adult Leukemia Study Group (JALSG), and foreign institutes. Fresh frozen plasma (FFP) was administered as a supplement in 46% patients in the JPLSG and 86% in the JALSG. The threshold level of FFP infusion was less than 100 mg/dl plasma fibrinogen in 70% of the JALSG and 20% of the JPLSG, while in another 20% of the JPLSG, FFP was administered when the fibrinogen level was less than 50 mg/dl. The preventive use of antithrombin products (AT) was prescribed in 93% of the JPLSG and 63% of the JALSG: The threshold level of AT supplementation was less than 70% of plasma antithrombin activity, which was similar in both groups. Most foreign institutes do not routinely use FFP or AT.
authors.affiliation: Division of Translational Research for Drug Development, Fukushima Medical University School of Medicine, Japan.
authors.forename: Chitose
authors.initials: C
authors.lastname: Ogawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Manabe
authors.forename: Akira
authors.initials: A
authors.lastname: Ohara
authors.forename: Akira
authors.initials: A
authors.lastname: Ishiguro
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000627:therapeutic use*; D001778:Blood Coagulation Disorders / Q000139:chemically induced / Q000188:drug therapy*; D001780:Blood Coagulation Tests / Q000379:methods; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D001215:Asparaginase